55910 Federal Register / Vol. 70, No. 184 / Friday, September 23, 2005 / Notices 

(4) Increase information 

dissemination and training, and 

(5) Improve coordination across the 

radiological health community. 

II. Agenda 

On October 31, 2005, FDA is 

providing the opportunity for a number 

of stakeholder organizations to discuss 

how they can assist FDA in 

implementing the program and in 

addressing important public health 

problems. FDA and its stakeholders will 

discuss the following aspects of the 

radiological health plan overview: 

• Standards—Discussion will 

consider the following topics: Increased 

reliance by FDA on consensus radiation 

safety performance standards, the role of 

national and international standards, 

and the role of State regulations in 

assuring product safety and proper use. 

• Monitoring the Use of Radiation—

Discussion will consider the following 

topics: The shift of CDRH’s focus from 

products to users, patients, and 

consumers; adverse event reporting; 

State program roles in ensuring 

appropriate use of radiation; facility 

quality assurance programs; and the 

establishment of a voluntary patient 

radiation dose reporting system for 

diagnostic imaging procedures that use 

ionizing radiation. This system could be 

used to monitor national exposure 

trends and provide a basis for 

establishing diagnostic reference levels 

of patient dose for use in facility quality 

improvement programs. 

• Monitoring the Industry—

Discussion will consider the following 

topics: The shift of FDA emphasis from 

testing products, to inspecting 

manufacturers to assure quality 

manufacturing and products; the 

reduction of reporting requirements; 

and the development of electronic 

reporting methods. 

• Education—Discussion will 

consider education and training for 

manufacturers, regulators, and users. 

On November 1, 2005, FDA will hold 

concurrent discussion sessions 

throughout the day on the Standards, 

Monitoring, and Education topics to 

provide further opportunity for 

stakeholder comment and discussion. 

FDA will provide an opportunity for 

comment during the public comment 

period for individuals and/or 

organizations on October 31, 2005. In 

addition, the agency will provide an 

opportunity to present individual 

viewpoints during the concurrent 

discussion sessions on November 1, 

2005. FDA reserves the right to limit the 

time of speakers during the public 

comment periods. 

III. Registration 

Participants must register for the 

meeting by October 17, 2005. 

Acceptance will be on a first-come, firstserved basis. There will be no onsite 

registration and unregistered 

participants will not be added to the 

program. Please register online at http:// 

www.fda.gov/cdrh/meetings/ 

120303.html. Persons without Internet 

access may register for the onsite 

meeting by calling 301–594–3309 by 

October 17, 2005. 

If you need special accommodations 

due to a disability, please fax 

information regarding those needs to 

Kaye Chesemore at 301–594–3306, at 

least 7 days in advance of the meeting. 

IV. Request for Suggestions, 

Recommendations, and Materials 

FDA is particularly interested in 

receiving suggestions from stakeholders 

related to the topics listed previously in 

this document. Send suggestions or 

recommendations to the Division of 

Dockets Management (see ADDRESSES). 

FDA will place an additional copy of 

any material it receives in the docket for 

this document (2005N–0375). 

Suggestions, recommendations, and 

materials may be seen at the Division of 

Dockets Management between 9 a.m. 

and 4 p.m., Monday through Friday (see 

ADDRESSES). 

V. Transcripts 

Following the meeting, transcripts 

will be available for review at the 

Division of Dockets Management (see 

ADDRESSES). 

Dated: September 19, 2005. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

[FR Doc. 05–19077 Filed 9–20–05; 3:31 pm] 

BILLING CODE 4160–01–S 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[FDA 225–04–8000] 

Memorandum of Understanding 

Between the Food and Drug 

Administration and the Food and Drug 

Administration Alumni Association 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is providing 

notice of a memorandum of 

understanding (MOU) between FDA and 

the Food and Drug Administration 

Alumni Association, Inc. The purpose 

of this MOU is to establish a greater 

collaboration between FDA and the 

Food and Drug Administration Alumni 

Association, Inc., regarding FDAs 2006 

Centennial Observance. 

DATES: The agreement became effective 

July 28, 2004. 

FOR FURTHER INFORMATION CONTACT: 

Mary Hitch, Senior Advisor, Office of 

External Relations (HF–10), 5600 

Fishers Lane, Rockville, MD 20857, 

301–827–4406. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 20.108(c), 

which states that all written agreements 

and MOUs between FDA and others 

shall be published in the Federal 

Register, the agency is publishing notice 

of this MOU. 

Dated: September 8, 2005. 

Jeffrey Shuren, 

Assistant Commissioner for Policy. 

BILLING CODE 4160–01–S 

Federal Register / Vol. 70, No. 184 / Friday, September 23, 2005 / Notices 55911 


EN23SE05.068</GPH>
55912 Federal Register / Vol. 70, No. 184 / Friday, September 23, 2005 / Notices 


EN23SE05.069</GPH>
Federal Register / Vol. 70, No. 184 / Friday, September 23, 2005 / Notices 55913 


EN23SE05.070</GPH>
55914 Federal Register / Vol. 70, No. 184 / Friday, September 23, 2005 / Notices 

[FR Doc. 05–19016 Filed 9–22–05; 8:45 am] 

BILLING CODE 4160–01–C 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

[CFDA 93.223] 

Cooperative Agreement for Border 

Health Best Practices 

AGENCY: Office of Rural Health Policy, 

HRSA, DHHS. 

ACTION: Notice of Single Source Award. 

SUMMARY: The Office of Rural Health 

Policy (ORHP), in cooperation with the 

Office of Global Health Affairs (OGHA), 

Office of Minority Health (OMH), Office 

on Women’s Health (OWH), and Centers 

for Disease Control and Prevention 

(CDC) will award a one year single 

source award to the U.S.-Mexico Border 

Health Association (USMBHA) to 

identify and promote best practices in 

border communities. As defined in the 

La Paz Agreement, the border region is 

100 km north and south of the 

international boundary line between the 

United States and Mexico. Funds will 

be used on both sides of the U.S.- 

Mexico border for the development of 

activities under the second annual 

Border Binational Health Week (October 

10–16, 2005). 

FOR FURTHER INFORMATION CONTACT: 

Elizabeth Rezai-zadeh, Office of Rural 

Health Policy, Room 9A–55, 5600 

Fishers Lane, Rockville, MD 20857. 

Telephone: 301–443–4107. E-mail: 

erezai@hrsa.gov. 

SUPPLEMENTARY INFORMATION: 

Intended Recipient of the Award 

U.S.-Mexico Border Health 

Association in El Paso, TX. 

Amount of the Award 

$383,000. 


EN23SE05.071</GPH>